Gsk (GSK) Net Equity Issued and Repurchased (2009 - 2026)

Gsk's Net Equity Issued and Repurchased history runs 18 years deep, the most recent figure standing at $10.8 million for Q1 2026.

• In Q1 2026, Net Equity Issued and Repurchased fell 28.64% year-over-year to $10.8 million; the TTM figure through Mar 2026 stood at $68.9 million (down 6.25% YoY), while the FY2025 annual figure was $19.8 million, down 22.64% from the prior year.
• Net Equity Issued and Repurchased for Q1 2026 stood at $10.8 million, down from $18.6 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $24.4 million in Q4 2024, with the low at $9.7 million in Q1 2023.
• The 5-year median for Net Equity Issued and Repurchased is $18.6 million (2025), against an average of $17.7 million.
• The sharpest annual moves came in 2023 and 2024: Net Equity Issued and Repurchased slumped 57.37% in 2023, then soared 134.81% in 2024.
• Gsk's Net Equity Issued and Repurchased stood at $23.5 million in 2022, then sank by 52.38% to $11.2 million in 2023, then soared by 118.31% to $24.4 million in 2024, then declined by 23.64% to $18.6 million in 2025, then tumbled by 42.08% to $10.8 million in 2026.
• Business Quant data shows GSK's Net Equity Issued and Repurchased at $10.8 million in Q1 2026, $18.6 million in Q4 2025, and $15.1 million in Q1 2025.